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Abstract 
Self-immolative spacers are a unique class of molecules employed in a variety of 
applications, particularly in the biomedical field.  Most commonly, they are molecules 
containing two reactive termini with a capping group at one terminus and a substrate of 
interest at the other.  Upon removal of the capping group, the spacer undergoes an 
intramolecular reaction that results in its removal from the molecule and liberation of the 
substrate.  These spacers have been extensively studied in monomeric form within prodrugs, 
as well as to form dendrimers that have been used for applications such as signal 
amplification, molecular logic gates and amplified drug release.  Their use to form polymeric 
systems, however, remains largely unexplored and undeveloped.  The work described in this 
thesis serves to expand this particular area of research, exploring the use of amine-based self-
immolative spacers in the context of self-immolative polymers. 
Two new polymeric systems were developed using N,N-dimethylethylenediamine in 
conjunction with first 4-hydroxybenzyl alcohol and then 2-mercaptoethanol.  In the first 
example, when a poly(ethylene glycol) end cap was used a block copolymer was formed that 
self-assembled in an aqueous environment and was capable of encapsulating a hydrophobic 
molecule and releasing it upon polymer degradation.  The second polymeric system was the 
first fully aliphatic self-immolative polymer, and when a disulfide end cap was employed 
polymer degradation could be triggered by the addition of dithiothreitol.  
Following this work, a series of novel self-immolative spacers derived from 4-
aminobutyric acid were developed in efforts to gain access to more rapidly cyclizing amine-
based spacers.  Carrying out modifications to the N and ! positions, a series of spacers were 
developed with half-lives of cyclization ranging from 2 – 39 s.  Lastly, these spacers were 
then combined with 4-hydroxybenzyl alcohol and 2’-hydroxyhydrocinnamic acid in efforts to 
develop novel 4-aminobutyric acid-based self-immolative polymers.   
Keywords 
Self-immolative, monomer, polymer, block copolymer, spacer, cyclization, electronic 
rearrangement, degradation, synthesis, kinetics. 
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Chapter 1  
Biodegradable and Self-Immolative Materials in Medical 
Applications! 
 
1.1 General Introduction 
Biodegradable polymers are an important class of materials with applications in diverse 
areas.  With uses from bulk commercial items such as biodegradable plastics to highly 
specialized drug delivery systems for the treatment of cancer, these polymers represent 
one of the most broadly applicable classes of materials.  Predominantly, they are 
polyesters such as polycaprolactone (PCL), poly(D/L-lactic acid) (PDLLA), poly(L-lactic 
acid) (PLLA),  or poly(glycolic acid) (PGA) (Figure 1.1), owing to their ease of 
synthesis, often in a single step through a ring-opening polymerization of readily 
available monomers (Scheme 1.1).  Additionally, other polyesters derived from diacids 
and diols have been employed, along with other backbones such as polyamides, 
polyanhydrides, polyphosphazenes, and more specialized polydisulfides, polyacetals, and 
poly(ortho ester)s (Figure 1.2).  Of particular interest to this thesis is their use in 
biomedical applications, including stents and sutures,1-3 tissue engineering4-9 and 
particularly as drug delivery vehicles.10-33  Recent advancements in the use of 
biodegradable polymers in each of these applications will be highlighted below. 
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Figure 1.1. Chemical structures of the most common biodegradable polyesters. 
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Scheme 1.1. Polymer synthesis from a) lactone; or b) cyclic dimer. 
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1.2 Biodegradable Polymers in Medical Applications 
Poly(hydroxyacid)s have received substantial attention for applications in biomedical 
devices.  They possess numerous desirable properties, such as biocompatibility, 
maintenance of tensile strength over time, and eventual breakdown into nontoxic 
degradation products.  Additionally, each polymer has unique physical properties, such as 
polymer morphology, glass transition temperature and melting point, as well as chemical 
properties such as degradation kinetics.  Furthermore, by developing copolymers of 
different monomeric units, the physical and chemical properties can be fine-tuned to fit a 
host of potential applications.    
Common polymers used in medical devices include PCL, PGA, PLLA, PDLLA, 
and more recently polydioxanone (PDS), as well as various combinations of these in 
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copolymers such as poly(D/L-lactic-coglyocolic acid) (PLGA).  In vivo degradation times 
of these polymers range from 1 – 2 months for 50/50 PLGA up to greater than two years 
for PCL and PLLA, with homopolymers generally having longer lifetimes than 
copolymers.1  This degradation timeline makes these materials well suited to a variety of 
medical applications such as sutures or stents, as the extended timeline allows the 
polymer to maintain tensile strength throughout the healing process while eventually 
degrading into small molecules, eliminating the need for additional procedures to remove 
the device.  
Numerous polyesters, both homopolymers and copolymers, have already been 
commercialized as degradable sutures.  These include products such as Vicryl" and 
Monocryl", copolymers of PGA-PLA and PCL-PLA, respectively, Dexon", a glycolic 
acid homopolymer, and PDS II", made from polydioxanone.2  In a report highlighting the 
development of Monocryl", the authors found that the material maintained approximately 
25% breaking strength after two weeks compared to greater than 80% retention for PDS 
II".  Analyzing the degradation, Monocryl" was found to undergo complete degradation 
in approximately 4 months. 
In 2008, Pektok and coworkers evaluated PCL nanofiber as a vascular graft 
material, comparing it to the more conventionally used expanded polytetrafluoroethylene 
(ePTFE).3  They found that PCL nanofibers were superior to ePTFE in healing capability, 
as faster endothelialization and extracellular matrix formation was observed.  
Degradation studies proved that the polymer was being broken down, with approximately 
20% reduction in molecular weight being observed after 24 weeks. 
Taking advantage of the healing capabilities and prolonged degradation times of 
these polymers, researchers have also investigated their potential application in scaffold-
based tissue engineering.  Scaffold-based tissue engineering is a technique used to repair 
a wide variety of damaged tissues in the body.  It involves the use of a biocompatible and 
degradable scaffold on which cells of a desired type can be seeded and then grown.  
Upon maturation, the cells are implanted into the body at the site of the injury, proliferate 
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and in turn heal the damaged site.  Throughout this process the polymer gradually 
degrades, resulting in its complete removal from the matrix. 
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Figure 1.3. Biodegradable polymers used in different tissue engineering applications. 
The types of tissues engineered by this process have included soft tissue, bone, 
smooth muscle, as well as cardiovascular tissues.  Each of these tissues requires scaffolds 
with different biocompatibilities, physical properties, and degradation timelines.  To this 
end, numerous biodegradable polymers have been developed which possess the 
properties desirable for each application.  With their elastic properties, PGA/PCL 
copolymers were found to be ideally suited to smooth muscle tissue engineering.8  For 
soft tissue engineering, a polymer with a lower tensile strength is desired and thus 
poly(ester urethane)ureas and similar polymers have been employed.7  Conversely, for 
bone tissue engineering, materials with much higher tensile strength are required, and 
materials such as poly(propylene fumarate)9 and a polycarbamate derived from lysine 
diisocyanate and glucose6 have been employed (Figure 1.3). 
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1.3 Drug Delivery Systems 
A very important and exciting application of biodegradable polymers is their use as drug 
delivery vehicles.  These vehicles are designed to increase drug bioavailability and 
effectiveness, particularly pertaining to more hydrophobic drugs, as well as reduce 
toxicity, and help control the dosage and release rate of the drug.  A number of polymeric 
systems have been developed to achieve this task, which can be divided into two major 
groups, both of which will be discussed in greater detail below.  The first group involves 
nonspecific biodegradable polymers, examples of which include polyesters,13,15-18,20-
22,32,33 polyphosphazenes,34-36 and polyanhydrides.19  The second group is stimuli 
responsive polymers, including polyketals,29-31,37 poly(ortho esters),38 disulfide containing 
polymers,28,39,40 polyelectrolytes,41-44 and a variety of others.  This second group can be 
further subdivided into two categories, degradable and non-degradable.  Degradable 
stimuli responsive polymers will break down into smaller molecules upon triggering, 
while non-degradable polymers, often referred to as bioresponsive polymers, will lose 
any kind of supramolecular assembly upon triggering, but the polymer chains themselves 
remain intact.  There are many types of triggering mechanisms, but those used in the 
context of drug delivery are primarily changes in pH and redox potential. 
 
1.3.1 Biodegradable Homopolymers 
Particle
formation
Polymer
degradation
Drug
release
Polymer and drug in solution Drug loaded
particle
Partially degraded polymer
and resulting drug release  
Scheme 1.2. Encapsulation & release from a biodegradable polymer particle. 
Within the first class of nonspecific biodegradable polymers, there have been primarily 
two approaches to using these as drug delivery agents.  The first approach involves the 
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synthesis of a homopolymer of the degradable material and its assembly into a 
nanoparticle or microparticle loaded with the drug to be delivered.  This is an attractive 
approach, as the polymers are formed in a single step from inexpensive starting materials, 
and numerous methods exist to create particles of various sizes.  A general method for 
particle formation and drug release is shown in Scheme 1.2, where the polymer and the 
drug are mixed together and then the particle is formed with the drug encapsulated.  
Additionally, the exterior of the particles can be coated with different materials for 
applications such as improved targeting or to promote cell adhesion.  Once the particles 
have been prepared, they can be injected into the body whereupon the polymer gradually 
degrades, releasing its payload. 
Particles of various sizes and compositions have been employed for a variety of 
applications.  For example, Benoit and coworkers demonstrated the capability of PCL 
microparticles as agents for oral vaccine delivery.32  Under various conditions they were 
able to synthesize particles ranging from 5 – 10 µm, a suitable size for oral delivery.  
Using bovine serum albumin (BSA) as a water-soluble model antigen, they demonstrated 
that the protein could be taken up inside the microparticle with loading efficiencies 
ranging from 1 – 36%.  Carrying out polymer degradation and release studies in vitro, 
they found that there was an initial burst release of approximately 25% of the protein, 
followed by the gradual release of a further 10% over the course of 80 h, leading to a 
maximum release of approximately 35%.  Analyzing the BSA released from the particles, 
they found it to be unchanged throughout the course of encapsulation and release.  While 
the authors did not investigate their system in vivo, their in vitro analyses demonstrated 
the proof of concept that their microparticles could be used for oral vaccine 
administration.  
Demonstrating that dual functions could be achieved, Newman and McBurney 
developed porous PLA/PGA microspheres for the uptake and delivery of cells for tissue 
engineering.18  In their study, they synthesized microspheres in the presence of retinoic 
acid (RA), a molecule used to induce cell differentiation into neurons. Following this, the 
microspheres were coated with laminin to promote cell adhesion and then added to P19 
embryonal carcinoma cell culture, a model of embryonic stem cells.  They found that 
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after one day, cells had begun to attach themselves to the surface of the microspheres, 
and by day four cells had encompassed many of the microspheres.  They observed that 
the cells exhibited a slight improvement in neuron formation when compared to cells 
cultured in the presence of free RA.  In studying biodegradation of the microspheres, the 
percent release of RA was monitored over a course of 125 h, and was found to be 50 – 
60%. 
Similar materials have also been investigated for the treatment of vascular injury.  
In a study performed by Chandy and coworkers, they demonstrated the ability of 
PLA/PCL microspheres to encapsulate cisplatin and slowly release the drug over the 
course of 30 days.22  They synthesized PLA/PCL microspheres in the presence of 
cisplatin, encapsulating the drug, and then coated the microspheres with either poly(vinyl 
alcohol) (PVA), poly(ethylene glycol) (PEG), chitosan or alginate.  These coatings were 
added to improve circulation time, as well as to slow the degradation time of the particle, 
thus slowing the release of the drug.  Carrying out release studies, they found that there 
was an initial burst release of between 20 – 30% of the drug within the first day with a 
more gradual release being observed over the remaining 29 days of the study.  They 
found that PVA-coated microspheres displayed the fastest release of cisplatin, with 
greater than 90% of the drug released after 30 days.  The remaining three coatings were 
similar, exhibiting approximately 75 – 85% release over the same time period, with PEG-
coated microspheres showing the slowest release profile.  Based on these findings, the 
authors demonstrated that PEG and alginate-coated PLA/PCL microspheres were indeed 
viable candidates for cisplatin drug delivery vehicles. 
While the above examples have demonstrated the effectiveness of micron-sized 
particles for drug delivery applications, there has also been significant investigation of 
similar materials on the nanoscale.  Nano-sized particles have been found to be ideally 
suited to traverse cellular membranes, making them extremely valuable as potential drug 
delivery agents.  Mu and Feng have demonstrated their potential in use in anti-cancer 
therapy.17  In their study, they synthesized PLA/PGA nanoparticles loaded with Taxol" 
(Tax), and demonstrated its controlled release from the nanoparticle.  Under optimized 
conditions, they were able to encapsulate Tax within the nanoparticles with 84% 
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efficiency.  In in vitro release studies, the results observed were similar to those of the 
microparticle studies described above.  There was an initial burst release of 
approximately 20% in the first day, and by day thirty 50 – 70% of the drug had been 
released from the carrier. 
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Figure 1.4. Various steroid-substituted polyphosphazenes. 
Polyphosphazenes have also been investigated as different class of potential drug 
delivery vehicles.35  Due to the possibility of varying the substituents on the phosphorus, 
the degradation kinetics of these polymers can be readily tuned by incorporating 
hydrophilic or hydrophobic substituents.  Additionally, there exists the possibility of 
incorporating the drug molecule directly onto the polymer backbone.  Provided the 
linkage is hydrolytically sensitive, this should allow for its gradual release from the 
polymer as the polymer breaks down.  This proof of concept was first demonstrated by 
Allcock and Fuller in 1980, when they synthesized a series of polyphosphazenes with 
various steroidal substituents incorporated on the backbone (Figure 1.4).34  The steroids 
were linked either through aryloxy or alkoxy groups to the phosphorus, and they found 
that while aryloxy-based phosphazenes were stable, the alkoxy-substituted ones were not.  
The authors did not carry out a thorough investigation of the release of the steroids upon 
degradation, but they did demonstrate this as a possible mechanism for drug delivery. 
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Figure 1.5. Polyphosphazenes synthesized for drug delivery. 
Allcock and Fuller also later reported imidazole and methylphenoxy co-
substituted polyphosphazene 1.21 for release of noncovalent drug molecules.  They 
varied the ratio of the two substituents to contain 20, 45 and 80% imidazole substitution, 
and found that 20% imidazole content showed the best release kinetics.36  Carrying out in 
vitro release studies on different compounds such as 4-nitroaniline, progesterone as well 
as BSA, they observed that contrary to polyester-based drug carriers discussed thus far, 
little or no burst release of the drug was observed.  The timeline of release was also found 
to be much faster than polyester-based delivery vehicles.  4-Nitroaniline was completely 
released within approximately 10 days, while progesterone was fully released within 30 
days.  While the 30-day timeline was the same that from the polyester carriers previously 
discussed, in those cases the drug continued to be released and the experiment was 
simply terminated, whereas in the polyphosphazene case the drug had been fully released 
from the polymer.  The only exception was with BSA, which was found to have much 
slower and incomplete release, as it began to level off at around 50% release after 3 
weeks.  These results have shown that polyphosphazenes represent a viable alternative to 
polyester-based drug delivery systems, and have great potential for further applications. 
 
1.3.2 Biodegradable Block Copolymer Assemblies for Drug Delivery 
Self-assemblies are the arrangements of material, in this case polymers, into ordered 
supramolecular structures.  While there are numerous driving forces for these assemblies, 
such as hydrogen bonding or charge-charge interactions, the driving force for the 
assemblies to be detailed in this section is primarily entropic in nature and relies on the 
hydrophobic and hydrophilic characteristics of the block copolymers.  By preparing 
polymers composed of a relatively hydrophobic polyester block connected to a more 
hydrophilic block such as PEG and then immersing them in water, the polymers 
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spontaneously arrange themselves in order to minimize contact of the hydrophobic blocks 
with water.  While these self-assemblies can vary in nature and size, to include spherical 
and worm-like micelles, vesicles, toroids, and others, only spherical micelles and vesicles 
(Figure 1.6) will be discussed here, as they have been most widely investigated for drug 
delivery applications.  A spherical micelle is an assembly where the hydrophobic chains 
of the polymers aggregate at the core while the hydrophilic chains surround it on the 
exterior, making up the corona.  A polymer vesicle, also referred to as a polymersome, is 
the macromolecular analogue of the liposome, an assembly composed of phospholipid 
surfactants that forms the basis for the membranes in living cells.  In this case, the 
hydrophobic chains make up the interior of the membrane, while the hydrophilic block 
contacts the water on both the interior and exterior of the vesicle. In general, the ability of 
an amphiphilic block copolymer to form micelles, vesicles, or other assemblies can be 
predicted based on the volume fractions of the hydrophobic and hydrophilic block, 
although the structure of the polymer, its rigidity, and crystallinity can also play a role.  
By selecting different polymers, varying the ratio between the hydrophilic and 
hydrophobic blocks, and employing different assembly methods, researchers are can 
obtain control over both the type of assembly formed, as well as its size. 
Spherical Micelle Polymer Vesicle  
Figure 1.6. Spherical micelle and vesicle. 
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1.3.2.1 Biodegradable Micelles for Drug Delivery 
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Figure 1.7. Encapsulation & release of drug from micelle. 
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Figure 1.8. Chemical structure of Doxorubicin. 
Polymer micelles are ideally suited for the delivery of hydrophobic drugs.  As shown in 
Figure 1.7, the drug molecules can be encapsulated within the hydrophobic core of the 
micelle and slowly leach out over time.  This increases the bioavailability of these drugs, 
which otherwise exhibit poor water solubility, and therefore limited efficacy within the 
body.  This is particularly relevant in anti-cancer therapy, as a number of drugs currently 
employed in treatments are quite hydrophobic and therefore have poor bioavailability on 
their own.  Of particular interest is the anti-cancer drug doxorubicin (Dox), shown in 
Figure 1.8.  Several recent reports have highlighted the possibility of using PCL-PEG 
block copolymer micelles as delivery vehicles for Dox.20,21,23 
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Figure 1.9. #-(carbamic acid benzyl ester)-$-caprolactone-modified polycaprolactone-
poly(ethylene glycol) micelle for Dox delivery. 
Lang and coworkers have recently reported a modified PCL-PEG micelle for Dox 
delivery.21  In addition to using $-caprolactone (CL), they incorporated #-(carbamic acid 
benzyl ester)-$-caprolactone (CABCL) into the hydrophobic block in either 10:1 or 2.5:1 
CL:CABCL ratio (Figure 1.9).  CABCL was a monomer they had recently developed for 
the purpose of encapsulating Dox, as it was found to have superior interactions with the 
drug compared to conventional $-caprolactone.   Having synthesized their block 
copolymers, they assembled them into micelles in the presence of Dox via dialysis and 
observed loading efficiencies of 47 and 69% for 10:1 and 2.5:1 polymer blends, 
respectively.  Examining release kinetics, they obtained a slow release profile of Dox 
from the micelles, with 10 – 15% of the payload being released over a course of 3 days 
compared to a 30% release of Dox from unmodified PCL-PEG micelles.  No substantial 
burst release was observed.  Their findings demonstrated that the incorporation of 
CABCL into the polymer backbone improved Dox internalization, making these potential 
candidates for slow release treatments. 
In a second example, Diao and coworkers tested their Dox-loaded PCL-PEG 
micelles for treatment of resistant K562 tumor cells.23  Dox-loaded micelles were 
prepared in this case through ultrasonication of a mixed organic-aqueous solution 
followed by evaporation of the organic solvent, and a loading efficiency of 49% was 
obtained.  In vitro release studies showed increased release relative to Lang and 
coworkers, with approximately 70% of encapsulated Dox being released after 4 days 
following an initial burst of approximately 20%.  Most importantly, when they tested 
their loaded micelles against Dox-resistant K562 tumor cells, they found that at dosages 
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of both 6 and 12 µg/mL, approximately 80% of the cells had been killed after 3 days of 
incubation, relative to just 50% when free Dox was used.  Their work has effectively 
demonstrated that the use of drug delivery vehicles is a potentially useful treatment 
option for drug-resistant in tumor cells. 
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Figure 1.10. Folate-terminated star-shaped polycaprolactone-poly(ethylene glycol) 
micelles. 
 
Figure 1.11. Folate-terminated micelles bind to a receptor and release a drug payload. 
Hsieh and coworkers have very recently developed a method to improve the targeting of 
tumor cells with Dox-loaded PCL-PEG star-shaped micelles.20  This may minimize the 
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harmful side effects often associated with chemotherapy.  Attaching folic acid to the end 
of the PEG block (Figure 1.10), they sought to take advantage of the fact that several 
tumor cell lines overexpress folate receptor proteins, whereas these proteins are expressed 
to much less extent in healthy tissue.  Thus, the folic acid-terminated micelles should 
preferentially bind to cancerous cells, resulting in Dox being primarily administered to 
these cells (Figure 1.11).  Dox-loaded micelles were formed by dialysis in a similar 
fashion to Lang’s work.  Once formed, release studies showed that a significant amount 
of the Dox was lost within the first hour, with approximately 30% release being observed.  
An additional 10% leached out over the next 12 h, at which point a maximum release of 
40% was obtained, and held constant over the course of 7 days.  To test the targeting 
efficiency of folic acid on the micelle, they incubated MCF-7 cells for 48 h in the 
presence of free Dox, Dox-loaded folic acid-terminated micelles, Dox-loaded hydroxy-
terminated micelles, and finally Dox-loaded folic acid-terminated micelles in the 
presence of free folic acid.  They found that their folic acid-terminated micelles showed 
the best cytotoxicity, with an observed cell viability of below 20%.  They also found that 
free folic acid indeed inhibited binding, with cell viability rising to approximately 25%.  
Micelles lacking targeting groups resulted in approximately 35% viability.  These 
findings verify that the addition of targeting groups can improve the delivery of anti-
cancer drugs to tumor cells, thus improving the potency of the drug. 
 
1.3.2.2 Biodegradable Vesicles for Drug Delivery 
Vesicles possess an advantage over micelles, in that they are capable of not only 
encapsulating hydrophobic molecules within the vesicle membrane, but also hydrophilic 
drugs in the aqueous core.  This allows greater flexibility in the choice of drug to be 
administered, and also opens the possibility of combination therapy, simultaneously 
releasing multiple drug molecules. 
In a recent example by Lee and Feijen, a variety of biodegradable polymer 
vesicles were synthesized and the hydrophobic membranes were loaded with fluorescein-
labeled Tax.16  Making use of different polyester groups as hydrophobic blocks, they 
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synthesized four different vesicles containing PEG with either PCL, PDLLA, PCL-b-
PDLLA or a random PCL/PDLLA copolymer acting as the hydrophobic block (Figure 
1.12).  Using a solvent injection method to generate the vesicles, they were able to 
achieve Tax loading efficiencies of 75 – 80%.  They analyzed the release over the course 
of 4 weeks, and found significant differences depending on the hydrophobic block.  PCL 
had the most rapid and complete release, resulting in nearly 100% release by the end of 
the study.  The random PCL/PDLLA copolymer released approximately 70% of its 
payload, while the block PCL-PDLLA and PDLLA on their own exhibited the slowest 
release rates, with approximately 50% of Tax release over 4 weeks in each case.  These 
findings demonstrate that the nature of the hydrophobic block plays a key role in the 
release profile of the drug, and offers insight into the potential to tune these systems to 
obtain controlled release of a drug. 
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Figure 1.12. Structures of block copolymers with varying hydrophobic groups, which 
were used for vesicle formation. 
Hammer, Therien, and coworkers have also investigated the potential of PCL-
PEO (PEO = poly(ethylene oxide)) vesicles for drug delivery.15  Their vesicles were 
formed through thin-film rehydration, followed by Dox incorporation into the core using 
an ammonium sulfate gradient.  Testing their release in vitro, they carried out studies at 
both pH 7.4 and 5.5.  In both cases an initial burst of approximately 20% was observed, 
after which time the release slowed substantially at pH 7.4, reaching a maximum of 
approximately 50%.  At pH 5.5, release was found to be both more rapid and more 
complete, with a maximum of approximately 70% release observed.  They also analyzed 
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the rate of Dox release, measured in % initial load/h.  The authors found two distinct 
release profiles, depending on the pH, and proposed two different release mechanisms, 
shown in Scheme 1.3.  At pH 7.4, a rapid release was observed initially, after which time 
the remaining contents slowly leaked out.  Throughout these domains, two different 
release rate constants were observed.  To account for this, they suggested that there was 
an initial leaching out of the drug through the intact vesicle walls, after which the 
remaining drug release occurred as a result of vesicle wall rupture as the polyester 
component began to hydrolyze.  At pH 5.5, a more steady release curve was observed, 
with a rate constant similar to that of the second phase of release in pH 7.4.  Therefore, 
the authors suggested that ester hydrolysis had occurred much more rapidly at pH 5.5, 
and all of the observed release was as a result of vesicle wall rupture.   
Mechanism 1
Vesicle Leakage
Mechanism 2'
Vesicle degradation
and drug release
Mechanism 2
pH 7.4 pH 5.5
pH 7.4
 
Scheme 1.3. pH dependence on release mechanism from polymer vesicles. 
As previously mentioned, the use of polymer vesicles allows for the possibility of 
utilizing a single drug carrier for combination therapy.  This potential was effectively 
demonstrated by Discher and coworkers.13  They synthesized vesicles from a mixture of 
PLA-PEO and polybutadiene (PBD)-PEO through thin film rehydration, after which they 
loaded them with Dox using a pH gradient method.  Tax was then incorporated by 
injecting a solution of Tax in MeOH into a buffered solution containing the vesicles, after 
which dialysis removed any unencapsulated drug.  They carried out release studies and 
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found that over the course of 3 days nearly 100% of the Dox had been released, while 
80% of Tax was released.  More importantly, they carried out in vivo studies in mice 
models and compared their drug-loaded vesicles to free Dox and Tax. They noted that 
after 3 days the tumor volumes were reduced by 60% relative to untreated tumors and did 
not increase in size for the remainder of the study.  Comparatively, free Dox and Tax 
reduced tumor size by approximately 45% after 3 days, but thereafter tumor volume 
began to increase. 
 
1.3.3 Advantages and Limitations of Polyesters in Drug Delivery 
These past examples have highlighted how the use of biodegradable drug delivery 
vehicles can offer significant advantages in therapeutic applications.  Their effectiveness 
at controlling dosage has been highlighted in multiple cases, and by using different 
polyester blocks, further control over the release kinetics can be obtained.  In therapeutic 
applications, the use of drug delivery vehicles has proven to be more effective than using 
the free drug, and in fact has even been shown to overcome resistance to a drug by 
different cell lines.  Lastly, the use of targeting groups on the periphery has also been 
shown to be effective in increasing localized dosage, maximizing therapeutic effect while 
minimizing side effects.  Despite these numerous advantages, there is a major limitation 
inherent to the use of these materials, namely that they all rely on uncontrolled hydrolysis 
of the polymer backbone.  While the overall rate can be affected by such parameters as 
pH or the length and nature of the polymer chain, there is still no way to control when 
and where hydrolysis occurs along the backbone. 
 
1.3.4 Stimuli Responsive Polymers 
To overcome the limitations of ester hydrolysis as a mechanism for the breakdown of 
materials and the release of drugs, over the past couple of decades much research has 
focused on the development of stimuli-responsive polymers.  These polymers are 
synthesized with specific functional groups incorporated that are sensitive to certain 
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changes in the environment.  Upon exposure to these changes, the functional groups 
react, triggering the breakdown of the structure and causing release of the payload 
(Scheme 1.4).  This section will discuss recent advances in this field, with the following 
subsections focusing on prominent types of triggering mechanisms.  
Polymer and drug
in solution
Aseembly with
encapsulated drug
Polymer disassembly
and drug release
StimulusPolymer assembly
Drug encapsulation
 
Scheme 1.4. Stimuli responsive polymers in drug delivery. 
 
1.3.4.1 pH Responsive Polymers 
The design of polymers responsive to changes in pH represents an important 
advancement for drug delivery, as tumors and inflammatory tissues, as well as other 
tissues, have been reported to be mildly acidic (ie. pH 5.8 – 7.4).45,46  The best types of 
treatments are those that deliver the drug molecule selectively to the damaged tissue 
while leaving healthy tissue untouched.  Therefore, any significant differences between 
healthy and damaged tissue can potentially be exploited for selective drug delivery.  A 
pH gradient is one such property.  Because certain damaged tissues are moderately acidic 
relative to healthy tissue, there exists the potential to utilize materials that break down 
more rapidly in acidic medium for drug delivery applications.  Much focus has been 
placed on exploiting this difference in pH, and some of the findings both in the areas of 
degradable and non-degradable materials will be highlighted below. 
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1.3.4.1.1 Acid Degradable Polymers 
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Scheme 1.5. Polyacetals as acid sensitive drug delivery vehicles. 
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Figure 1.13. Series of polyamidoamines containing acid-sensitive acetals and ketals. 
The most widely used functional groups for degradable pH-sensitive materials are 
acetals and ketals.  These groups are well known to be stable under neutral or basic 
media, but readily undergo hydrolysis under acidic conditions.  Therefore, they are 
ideally suited for drug delivery applications, as they remain stable under physiological 
conditions but can break down upon exposure to the more acidic medium encountered 
within a tumor cell, triggering polymer degradation and release of the payload (Scheme 
1.5).  This concept was demonstrated by Fréchet and coworkers, through the synthesis of 
polymers containing acetal, dimethylketal, or aromatic ketals (Figure 1.13).37  Comparing 
relative hydrolysis rates at pH 7.4 and pH 5.0, they observed marked enhancements at 
lower pH.  The half-life of polymer 1.31 dropped from 161 to 81 days, while that of 1.32 
went from 6 to 0.03 days, and lastly 1.33 decreased from 15 to 3 days at pH 5.0 relative 
to pH 7.4.  This demonstrates that the use of a ketal linkage within the backbone can 
provide significant enhancement in degradation rates. 
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Figure 1.14. Polyacrylamide with acetal crosslinking groups. 
In a more recent example from the same group, crosslinked polyacrylamide 1.34, 
shown in Figure 1.14, was investigated for use in protein delivery.29  Acrylamide and a 
benzaldehyde acetal-containing bis(acrylamide) were copolymerized in the presence of 
BSA, forming BSA-loaded crosslinked microparticles.  To evaluate the release kinetics, 
they carried out experiments at both pH 5.0 and 7.4.  At pH 5.0 they observed complete 
release of BSA after 7 h, while at pH 7.4 less than 20% release had occurred over a 
period of 20 h, effectively demonstrating their potential applications in drug delivery. 
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Scheme 1.6. Particle formation and release from polyketal 1.35. 
In another example, Murthy and coworkers designed a ketal-containing polymer 
as a drug delivery vehicle for the treatment of inflammatory diseases.30  They synthesized 
polymers with the general structure 1.35 containing varying ratios of 1,4-
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cyclohexanedimethanol and 1,5-pentanediol linked via dimethylketal groups, and 
prepared microparticles from these polymers.  Testing their degradation rates, they found 
that the ideal ratio was 2.5:1 1,4-cyclohexanedimethanol:1,5-pentanediol, and used this 
polymer for in vitro and in vivo tests.  Beginning with in vitro release of rhodamine B, 
they observed complete release of the molecule within 4 days at pH 4.5, compared to 
approximately 65% at pH 7.4.  For in vivo studies, they tested mice suffering from liver 
damage by treating them with imatinib-loaded microparticles, using alanine 
aminotransaminase (ALT) levels in the mice to evaluate the therapeutic effects.  They 
found that at low concentrations the drug-loaded particles offered no improvement over 
free imatinib, but as concentrations rose the drug-loaded particles became extremely 
effective, reducing ALT to almost zero at the highest dosage, thus demonstrating the 
potential of this strategy for further treatments. 
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Figure 1.15. Acid-sensitive poly(ortho ester amide) 1.39. 
While the previous examples have focused on acetal and ketal linkages as acid-
sensitive groups, there has also been some focus on utilizing ortho esters for this same 
role.  Wang and coworkers demonstrated this possibility by developing a series of 
poly(ortho ester amides) (Figure 1.15).38  Following polymer synthesis, they prepared 
hydrogels containing FITC-labeled dextran, and tested the release kinetics.  They 
measured both polymer mass loss as well as dextran release at pH 5.0 and 7.4.  They 
found that at pH 5.0, complete mass loss was observed after 10 days, corresponding to 
full dextran release along the same timeline, while at pH 7.4 only approximately 25% 
mass loss and 25% dextran release was observed.  Thus, they showed that poly(ortho 
esters) are also viable candidates for pH sensitive drug delivery. 
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1.3.4.1.2 Non-Degradable pH Responsive Polymers 
Kataoka and coworkers designed a polymer for drug delivery that itself is stable to pH, 
but contains drug molecules covalently bound to the polymer via acid sensitive 
linkages.25  Utilizing a PEG-poly(aspartic acid) block copolymer, they modified the 
carboxylate sidechain and covalently bound Dox through a hydrazone linkage.  At 
physiological pH, Dox remains bound to the block copolymer micelle, but upon exposure 
to mild acid, the hydrazone was cleaved, releasing Dox from the micelle (Scheme 1.7).  
To verify this, they incubated their micelles at a range of pHs from 7.5 down to 3.0, and 
measured the release of Dox over a period of 3 days.  At pH 7.5, no release was observed 
throughout the course of the experiment, while at pH 3 they observed 100% release.  At 
the more relevant pH ranges of 4.5 – 6.5, the amount of released Dox ranged from 5 – 
45% as the pH decreased.  This demonstrates a highly effective and innovative technique 
for anti-cancer treatment, as near complete selectivity was achieved for release in more 
acidic environment versus in conditions mimicking those of healthy tissues.   
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Scheme 1.7. Covalent binding of Dox to block copolymer 1.40 via hydrazone linkage 
followed by acid catalyzed hydrolysis. 
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Figure 1.16. a) poly(2-(dialkylamino)ethyl) methacrylate structure and b) poly(2-
(dimethylamino)ethyl)-b-(2-(diethylamino)ethyl) methacrylate. 
A number of other examples that make use of non-degradable polymers as pH 
responsive drug delivery vehicles have also been reported.  For these systems, basic 
functional groups have typically been employed.  One of the most extensively 
investigated classes of non-degradable pH responsive polymers is 
poly((dialkylamino)ethyl methacrylate)s 1.42 (Figure 1.16a).41,43  For example, Armes 
and coworkers developed the first block copolymer of 2-(dimethylamino)ethyl 
methacrylate and 2-(diethylamino)ethyl methacrylate, shown in Figure 1.16b.43  They 
performed a series of experiments at varying pHs and noted a significant drop in surface 
tension of the solution in the pH range 6 – 8, corresponding to a change in polymer 
morphology.  Additionally, they found that the hydrodynamic size reached a maximum at 
pH 9.5, indicating micellization of the block copolymer. 
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Figure 1.17. Block copolymer of poly(2-vinylpyridine) and poly(ethylene oxide). 
Another example by Webber and coworkers made use of poly(2-vinylpyridine) 
and PEO as a pH-sensitive block copolymer (Figure 1.17).44  In their study, they found 
that micellization occurred at approximately pH 5, while below that the polymer chains 
existed as unimers.  While no further drug release studies were carried out, this example 
indeed shows great promise.  At physiological pH, the block copolymer exists primarily 
as micelles.  However, if exposed to acidic tissue, the pyridine groups protonate in the 
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mildly acidic medium, making them hydrophilic and rupturing the micelle, releasing its 
contents. 
 
1.3.4.2 Reduction Sensitive Polymers 
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Scheme 1.8. Disulfide-containing polymers as drug delivery vehicles. 
Reduction sensitive polymers have also been developed, and typically involve disulfide 
linkages.  This strategy takes advantage of the fact that the extracellular environment is 
typically oxidizing with glutathione concentrations on the order of micromolar, while the 
interior of a cell is reducing with millimolar concentrations of glutathione.  Therefore, the 
use of a disulfide-containing polymer offers stability of the delivery vehicle outside of the 
cell, limiting the risk of unwanted degradation.  Once inside the cell, the disulfide bond 
will be reduced, breaking down the polymer and releasing the payload entirely within the 
cell (Scheme 1.8).  
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Figure 1.18. Disulfide-containing polyamidoamine 1.45. 
A common backbone utilized for these polymers has been a disulfide-linked 
polyamidoamine.  In a study by Ferruti and coworkers, a polymer containing disulfide-
linked cysteine groups and piperazine dicarboxylates, 1.45, was synthesized and its 
breakdown in both the presence and absence of 2-mercaptoethanol as a reducing agent 
was evaluated.39  They found that the polymer was susceptible to hydrolysis in buffered 
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media, with 10 – 20% molecular weight (MW) reduction observed after 1 day and 
complete degradation occurring within a week.  However, this degradation rate was 
substantially improved in the presence of 2-mercaptoethanol, with a 50% MW reduction 
within a day, and 90% MW reduction occurring within 2 days.  
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Figure 1.19. Disulfide-containing poly(amido ethyleneimine) 1.46. 
Kim and coworkers sought to apply this general polymer backbone for gene 
delivery, utilizing poly(amido ethyleneimine) 1.46 (Figure 1.19).28  Taking advantage of 
the cationic ethyleneimine portion of the polymer backbone, they tested its ability to 
complex DNA, and found that complete complexation occurred when a 1.5:1 or higher 
w/w ratio of polymer:DNA was employed.  Testing complex stability using gel 
electrophoresis, they found them to be stable in buffered solution in the absence of any 
reducing agents.  Upon addition of dithiothreitol (DTT), complete release of the DNA 
was observed across all polymer:DNA ratios.  Based on these results, polymer 1.46 has 
shown good promise for applications in intracellular gene delivery. 
 
O
S
S
N
H
O
H
N
m
1.47
H
N
Ac
O
HN
HN
NH2
O
NHO
HN
H2N
 
Figure 1.20. Poly(ethylene glycol)-polyaspartate copolymer linked via disulfide. 
Looking at a different polymeric structure, Kataoka and coworkers designed 
block copolymer micelles from PEG and diethylenetriamine-substituted poly(aspartic 
acid) containing a disulfide group as the linker between the two blocks (Figure 1.20).40  
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Similar to Kim’s work, they utilized the amino groups to form complexes with the DNA, 
synthesizing a series of complexes with varying N/P ratios.  They found that for N/P 
ratios greater than 2:1 they achieved complete complexation of DNA.  Carrying out in 
vitro degradation studies, they found that at sufficiently low concentrations of DTT (10 
µM), the micelle structure remained stable.  At 10 mM DTT, complete rupture occurred 
within 1 h.  They also carried out cell transfection studies, and found that gene delivery 
began to occur within 11 h and 16 h for HeLa and 293T cells, respectively.  This result 
effectively demonstrates the possibility of these systems for use in gene therapy. 
 
1.3.4.3 Thermoresponsive polymers 
 
Scheme 1.9. a) Polymer in solution below and above LCST. b) Thermoresponsive 
polymer used for drug delivery. 
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Figure 1.21. Chemical structure of poly(N-isopropylacrylamide). 
The third and final major class of stimuli responsive polymers utilized for drug delivery 
systems is thermoresponsive polymers.  These polymers have the unique property of 
possessing a lower critical solution temperature (LCST) in water.  The lower critical 
solution temperature is the maximum temperature at which the polymer is soluble, above 
which it precipitates out of solution (Scheme 1.9a).  This property has been exploited by 
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using polymers possessing LCSTs at or near physiological temperatures in water for drug 
delivery applications, with the basic principle being that the polymer-drug complex is 
formed at room temperature when the polymer is soluble, and then after injection into the 
body and upon warming, the polymer precipitates out and the drug contents are released 
(Scheme 1.9b).  The most thoroughly investigated thermoresponsive polymer, for drug 
delivery as well as a host of other applications, has been poly(N-isopropylacrylamide) 
(PNIPAm) (Figure 1.21).  More recently, however, additional methacrylate-based 
polymers have also been investigated, and found to have similar thermoresponsive 
properties. 
Ge and coworkers studied a crosslinked PNIPAm network for drug delivery 
applications.12  Following the synthesis of crosslinked networks by two methods, 
conventional radical polymerization and frontal polymerization, they tested the products 
of each for drug loading capacities and drug release kinetics.  Using aspirin as a model 
drug, they found a 30% increase in drug loading capacity using frontal polymerization.  
To evaluate release kinetics, they studied both polymers at 25 °C and 37 °C, and found 
that the polymer produced from frontal polymerization exhibited both a more rapid and 
smoother release profile at 25 °C, reaching 100% release after 12 h versus 48 h for the 
conventional polymer.  Interestingly, the release slowed down drastically upon heating to 
37 °C, with 3 weeks being required for both polymers to release 90% of their payloads.  
While surprising, they attribute this slow release primarily to hydrophobic effects keeping 
the drug trapped within the polymer network. 
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Scheme 1.10. Conjugation and release of Dox from poly(N-isopropylacrylamide) 
hydrogel. 
NIPAm has also been combined with other monomers to form multifunctional 
polymeric structures that are both thermo- and pH-responsive.  This strategy was 
employed effectively by Zhao and coworkers, who prepared a crosslinked copolymer 
composed of NIPAm, methacrylic acid, and N,N’-methylenebisacrylamide as a 
crosslinker.11  Using this, they conjugated Dox to the acid groups through an acid-
sensitive hydrazone linkage (Scheme 1.10).  In the evaluation of these Dox-conjugated 
nanogels, they noted significant thermoresponsivity, with the size dropping from 375 nm 
at 25 °C to 135 nm at 37 °C.  This did not result in substantial release of Dox, as only 
20% release was observed over a course of 6 days.  When the pH was decreased to 5.3, 
however, greater than 70% release of Dox was noted.  They further tested their drug 
delivery system in cell viability assays at pH 7.4 and 6.8 at 37 °C and 43 °C.  It was 
found that changing one of the variables did not lead to any significant changes, whereas 
lowering the pH and heating the solution to 43 °C resulted in cell viability dropping to 
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65%.  While they did not carry out cell studies at lower pH, based on the release profile 
they proposed that this would be an effective drug delivery vehicle for hyperthermal 
cancer treatment. 
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Figure 1.22. Thermoresponsive polymer 1.52, a proposed alternative to poly(N-
isopropylacrylamide). 
In addition to PNIPAm, other acrylate-based polymers have also been studied for 
thermoresponsivity.   Lutz and coworkers have recently developed methacrylate polymer 
1.52, a random copolymer of 2-(2-methoxyethoxy)ethyl methacrylate and oligo(ethylene 
glycol) methacrylate (Figure 1.22).47  Comparing its physical characteristics directly to 
PNIPAm, they found that it was superior to PNIPAm in a variety of aspects of its LCST 
behaviour.  First, they found it had a smaller temperature gradient and hysteresis between 
heating and cooling cycles.  Additionally, it was found to consistently maintain a lower 
LCST than NIPAm in a variety of scenarios, such as changing salt concentration, 
polymer concentration, as well as polymer chain length.  From these findings, the authors 
suggest polymethacrylate 1.52 as a viable alternative to PNIPAm, though as of yet no 
application studies have been carried out. 
 
1.3.4.4 Polymers Responsive to Other Stimuli 
While pH, reduction and thermosensitive polymers represent the bulk of stimuli 
responsive materials studied for biological applications, there are some noteworthy 
examples of polymers responsive to other stimuli being employed for biological 
applications.  The groups of Morris and Zhao have developed a light sensitive block 
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copolymer micelle composed of PEG and polymethacrylate with photosensitive pendant 
groups26.  Upon exposure to either UV (365 nm) or NIR (794 nm) light, the ester group is 
cleaved, making the methacrylate portion of the block copolymer hydrophilic and thus 
rupturing the micelle (Scheme 1.11).  Using Nile Red and a coumarin dye as model 
drugs, they monitored the decrease in fluorescence over time upon exposure to both 
wavelengths.  Exposure to UV light resulted in much faster release, with the fluorescence 
decreasing by 60% within 40 min.  When the same copolymer micelle was exposed to 
NIR light, the fluorescence decreased by 60% within 5 h.   
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Scheme 1.11. Release of coumarin dye 1.55 from polymer 1.53 upon irradiation with UV 
or NIR light. 
In another example, Kataoka and coworkers have developed a thermoresponsive 
polymer that is highly sensitive to glucose concentrations for the treatment of diabetes 
(Scheme 1.12).24  Incorporating a small amount of phenylboronic acid-substituted 
acrylamide into PNIPAm, they found that glucose concentration played a dramatic role in 
determining the LCST of the polymer.  In the absence of glucose, the LCST was 
approximately 22 °C.  As the concentration of glucose was gradually increased up to 5 
g/L, the LCST correspondingly increased to 35 °C.  They then tested the polymer gel’s 
potential for insulin delivery by carrying out release studies at 28 °C and pH 9.0 with 
varying glucose concentration.  With no glucose, approximately 10% insulin release was 
observed after 24 h.  At 1 g/L of glucose, 30% was released over the same time period. 
Finally, at 3 g/L 80% was released.  While the parameters for these tests were outside of 
physiological temperature and pH, they still effectively demonstrate the possibility for a 
system of this nature to be employed for diabetes treatment. 
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Scheme 1.12. Complexation of 1.56 with glucose and resultant precipitation. 
 
1.3.4.5 Advantages and Limitations of Stimuli Responsive 
Polymers 
The examples described above highlight the effectiveness of stimuli responsive polymers 
for biological applications.  Their main advantage is their ability to release their 
therapeutic payload in response to changes in conditions, such as pH, reduction potential, 
temperature or other stimuli. This can potentially allow for a more localized release, 
providing enhanced efficacy in treatments, and minimal side effects.  However, they do 
possess limitations.  For example, in the case of pH, there is only a small pH gradient that 
exists within the body so it is difficult to synthesize materials that can be highly sensitive 
within such a small range.  While the research thus far has indeed been promising and 
substantial increases in release rates have been obtained by slight decreases in pH, there 
is invariably uncontrolled release occurring.  While disulfide-containing polymers 
address the issue of nonspecific degradation to some degree, as degradation outside of a 
cell is minimized, an additional targeting group is often required to preferentially deliver 
drug payloads to diseased cells. Lastly, with body temperature remaining constant at 37 
ºC, it is difficult to employ thermoresponsive polymers in vivo, unless their LCSTs can be 
modulated by other chemical factors, such as was demonstrated with glucose-sensitive 
thermoresponsive hydrogels.   
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1.4 Introduction to Self-Immolative Materials 
To address a number of the above challenges and to further develop the field of 
polymeric materials in biomedical applications, there has been a recent focus on a new 
class of degradable polymers called self-immolative polymers.  Composed of a unique 
class of monomers called self-immolative spacers that are capable of undergoing 
intramolecular cleavage reactions, they are a new class of stimuli-responsive polymers 
that require just a single triggering event to induce complete depolymerization.  
Containing an end cap at one terminus, these polymers maintain their stability as long as 
the end cap remains attached.  Once the end cap is removed, a cascade of intramolecular 
cleavage events ensues, resulting in stepwise, end-to-end degradation of the polymer.  By 
using different functional groups as an end cap, depolymerization can be triggered under 
a variety of conditions or in response to a variety of different molecules present in 
solution.  Additionally, because only a single triggering event is required, the sensitivity 
to stimuli is greatly increased, with only trace amounts of an effector being required to 
induce depolymerization.   
While the field of self-immolative polymers is relatively new and unexplored, that 
of self-immolative spacers is much more widely studied.  Beginning as a capping group 
for prodrugs, their usage has gradually expanded to include short oligomeric species, 
dendrimers, and most recently linear self-immolative polymers, for a variety of 
applications such as drug delivery, signal amplification and logic gates.  A review of 
these areas is presented in the following sections. 
 
1.5 Self-Immolative Spacers 
A class of molecules termed self-immolative spacers has been a principle component in 
the design of all self-immolative materials.  Originally developed for the field of prodrug 
chemistry, such linkers were designed to overcome steric limitations by increasing the 
physical distance between the parent drug and the cleavage site as well as to alter the 
inherent stability of this linkage.48  In the absence of a self-immolative spacer, prodrugs 
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could be composed of a specifier conjugated directly to the parent drug by an enzyme-
labile linkage.49-52  Unfortunately, due to the demanding steric requirements of the 
enzymatic cleavage step, such prodrugs were found to be relatively ineffective.53-55  
Introduction of a spacer (Figure 1.24a) capable of undergoing a spontaneous 
intramolecular reaction to release the drug in its parent, active form, increased the 
accessibility of the cleavage site, enhancing drug release.56  
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Figure 1.23. a) Schematic of a prodrug comprising a specifier/trigger, spacer and drug; b) 
general structure of electronic cascade spacers; and c) general structure of cyclization 
spacers. 
The first self-immolative spacer introduced by Katzenellenbogen and coworkers 
in 1981 was based on 4-aminobenzyl alcohol.48  Commonly referred to as a 1,6-
elimination spacer, it is an example of an electronic cascade spacer, where unmasking of 
an aromatic amine,48 hydroxyl,57 or thiol58 moiety allows these chemical functionalities to 
become electron-donating, initiating an electronic cascade leading to release of a free 
drug or other leaving group, often following a subsequent decarboxylation reaction  
(Figure 1.23b).  As shown in Figure 1.23c, spacers based on cyclization reactions have 
also been introduced, whereby the unmasking of a nucleophilic functional group permits 
cyclization.59,60 In general, electronic cascade spacers react more rapidly than the 
cyclization spacers. Since their introduction, a variety of spacers based on both electronic 
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cascades and cyclization reactions have been developed and they have been applied in 
various prodrug,58,61-70 sensor,71-81 and drug delivery systems.82-88  
1.6 Self-Immolative Oligomers 
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Figure 1.24. a) Spacers based on extended aromatic systems such as naphthyl and 
biphenyl moieties that did not ungergo the desired electronic cascade eliminations; b) 
Spacers based on multiple 1,6-elimination spacers in sequence; and c) Spacers based on 
multiple 1,6-elimination spacers followed by a cyclization spacer (PG = protecting group, 
D = drug). 
Self-immolative oligomers were introduced by Scheeren and coworkers in 2001 as 
potential improvements to the spacers previously employed in prodrug systems.89  It was 
hypothesized that the use of elongated linkers might enhance the cleavage rates by further 
separating the cleavage site from the sterically bulky parent drug.  Linkers based on 
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extended aromatic systems such as naphthyl and biphenyl moieties (Figure 1.24a) were 
prepared.  However, these systems failed to undergo the electronic cascade leading to 
drug release, a result that was attributed to the high energetic cost of dearomatization 
associated with the required 1,8- and 1,10-elimination reactions.  In addition, the 
repulsion of ortho hydrogens in the biphenyl system would disfavor the planar 
intermediate structure.  In contrast, the combination of multiple 1,6-elimination spacers in 
sequence (Figure 1.24b) linking a plasmin sensitive specifier and the drug Tax or Dox, 
led to significantly enhanced drug release rates in the presence of the enzyme, when 
compared with analogous systems containing only one linker.  In addition, it was 
demonstrated that a diamine cyclization spacer (Figure 1.24c) could be incorporated into 
the sequence of linkers, also resulting in enhanced enzymatic cleavage rates relative to 
the single spacer system.  In this work, the prodrugs containing only electronic cascade 
spacers released the free drug more rapidly than those incorporating the cyclization 
spacers.  However, the diamine cyclization spacer provided the opportunity to conjugate 
hydroxyl-containing parent drugs via stable carbamate linkages instead of the less stable 
carbonate linkages that would be generated using the 1,6-elimination spacers alone.  
While none of the above systems resulted in an amplification of the biological stiumulus, 
the groundwork was laid for the synthesis of future linear and dendritic systems.  It was 
also demonstrated that the electronic cascade and cyclization reactions utilized in self-
immolative spacers could be extended to multimeric systems.  Since then, several other 
examples of oligomeric combinations of self-immolative spacers have been reported and 
demonstrated to undergo reaction cascades to release reporter molecules.65,74,79,90-93 
The first example of a self-immolative oligomer that led to chemical amplification 
was reported several years later by Warnecke and Kratz.94  This molecule, termed a 
"linear self-eliminating system", was composed of a sequence of three 1,6-elimination 
spacers (Scheme 1.13).  In contrast to the above oligomers, which only carried a drug 
payload at one terminus of the oligomer, amplification was achieved in this case by the 
conjugation of a model drug to aromatic moieties such that it could be released by a 1,4-
elimination reaction.  Kinetic studies revealed that cleavage of the oligomer backbone by 
the sequence of 1,6-elimination reactions was the faster process, while the release of 
drugs via the 1,4-elimination occurred more slowly.  In this system, tryptamine was used 
